The muscular dystrophies

Seminars in Neurology

Volumn 32, Issue 3, 2012, Pages 255-263

  Flanigan, Kevin M ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

dystrophinopathy; facioscapulohumeral; limb girdle; muscular dystrophy

Indexed keywords

ALPHA DYSTROGLYCAN; ATALUREN; COLLAGEN TYPE 6; CYCLOSPORIN A; DEFLAZACORT; GENTAMICIN; LOSARTAN; PREDNISONE; SELENOPROTEIN;

AEROBIC EXERCISE; ARTICLE; BECKER MUSCULAR DYSTROPHY; BEHAVIOR DISORDER; BONE MINERALIZATION; CARDIOMYOPATHY; CORTICOSTEROID THERAPY; CUSHING SYNDROME; DUCHENNE MUSCULAR DYSTROPHY; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; GENE MUTATION; HUMAN; LIMB GIRDLE MUSCULAR DYSTROPHY; MUSCLE BIOPSY; MUSCULAR DYSTROPHY; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; WEIGHT GAIN;

ADRENAL CORTEX HORMONES; ANIMALS; ANTI-INFLAMMATORY AGENTS; DYSTROPHIN; HUMANS; MUSCULAR DYSTROPHIES; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; MUSCULAR DYSTROPHY, DUCHENNE; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL;

EID: 84868239216     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0032-1329199     Document Type: Article

References (128)

1. Koenig M., Hoffman E. P., Bertelson C. J., Monaco A. P., Feener C., Kunkel L. M. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell: 1987; 50 3 509 517
2. McMillan H. J., Gregas M., Darras B. T., Kang P. B. Serum transaminase levels in boys with Duchenne and Becker muscular dystrophy. Pediatrics: 2011; 127 1 e132 e136
3. Urganci N., Arapolu M., Serdarolu P., Nuholu A. Incidental raised transaminases: a clue to muscle disease. Ann Trop Paediatr: 2006; 26 4 345 348
4. Monaco A. P., Bertelson C. J., Liechti-Gallati S., Moser H., Kunkel L. M. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics: 1988; 2 1 90 95
5. Flanigan K. M., Dunn D. M., von Niederhausern A., et al. United Dystrophinopathy Project Consortium Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Hum Mutat: 2009; 30 12 1657 1666
6. McDonald C. M., Abresch R. T., Carter G. T., Fowler W. M. Jr, Johnson E. R., Kilmer D. D. Profiles of neuromuscular diseases. Becker's muscular dystrophy. Am J Phys Med Rehabil: 1995; 74 5, Suppl S93 S103
7. Flanigan K. M., Dunn D. M., von Niederhausern A., et al. DMD Trp3X nonsense mutation associated with a founder effect in North American families with mild Becker muscular dystrophy. Neuromuscul Disord: 2009; 19 11 743 748
8. Dent K. M., Dunn D. M., von Niederhausern A. C., et al. Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort. Am J Med Genet A: 2005; 134 3 295 298
9. Flanigan K. M., von Niederhausern A., Dunn D. M., Alder J., Mendell J. R., Weiss R. B. Rapid direct sequence analysis of the dystrophin gene. Am J Hum Genet: 2003; 72 4 931 939
10. Yan J., Feng J., Buzin C. H., et al. Three-tiered noninvasive diagnosis in 96% of patients with Duchenne muscular dystrophy (DMD). Hum Mutat: 2004; 23 2 203 204
11. Mendell J. R., Shilling C., Leslie N. D., et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol: 2012; 71 3 304 313
12. Disset A., Bourgeois C. F., Benmalek N., Claustres M., Stevenin J., Tuffery-Giraud S. An exon skipping-associated nonsense mutation in the dystrophin gene uncovers a complex interplay between multiple antagonistic splicing elements. Hum Mol Genet: 2006; 15 6 999 1013
13. Gurvich O. L., Tuohy T. M., Howard M. T., et al. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy. Ann Neurol: 2008; 63 1 81 89
14. Arechavala-Gomeza V., Graham I. R., Popplewell L. J., et al. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther: 2007; 18 9 798 810
15. Arechavala-Gomeza V., Kinali M., Feng L., et al. Immunohistological intensity measurements as a tool to assess sarcolemma-associated protein expression. Neuropathol Appl Neurobiol: 2010; 36 4 265 274
16. Taylor L. E., Kaminoh Y. J., Rodesch C. K., Flanigan K. M. Quantification of dystrophin immunofluorescence in dystrophinopathy muscle specimens. Neuropathol Appl Neurobiol: 2012; doi: 10.1111/j.1365-2990.2012.01250.x (Epub ahead of print)
17. Arechavala-Gomeza V., Kinali M., Feng L., et al. Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials. Neuromuscul Disord: 2010; 20 5 295 301
18. Anthony K., Cirak S., Torelli S., et al. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain: 2011; 134 Pt 12 3547 3559
19. Neri M., Torelli S., Brown S., et al. Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. Neuromuscul Disord: 2007; 17 11-12 913 918
20. Manzur A. Y., Kuntzer T., Pike M., Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev: 2008; 1 CD003725
21. Biggar W. D., Politano L., Harris V. A., et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscul Disord: 2004; 14 8-9 476 482
22. Escolar D. M., Hache L. P., Clemens P. R., et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology: 2011; 77 5 444 452
23. Merlini L., Cicognani A., Malaspina E., et al. Early prednisone treatment in Duchenne muscular dystrophy. Muscle Nerve: 2003; 27 2 222 227
24. Bach J. R., Martinez D., Saulat B. Duchenne muscular dystrophy: the effect of glucocorticoids on ventilator use and ambulation. Am J Phys Med Rehabil: 2010; 89 8 620 624
25. Biggar W. D., Harris V. A., Eliasoph L., Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord: 2006; 16 4 249 255
26. Malik V., Rodino-Klapac L. R., Viollet L., et al. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol: 2010; 67 6 771 780
27. Welch E. M., Barton E. R., Zhuo J., et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature: 2007; 447 7140 87 91
28. Goemans N. M., Tulinius M., van den Akker J. T., et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med: 2011; 364 16 1513 1522
29. van Deutekom J. C., Janson A. A., Ginjaar I. B., et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med: 2007; 357 26 2677 2686
30. Cirak S., Arechavala-Gomeza V., Guglieri M., et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet: 2011; 378 9791 595 605
31. Kinali M., Arechavala-Gomeza V., Feng L., et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol: 2009; 8 10 918 928
32. Rodino-Klapac L. R., Chicoine L. G., Kaspar B. K., Mendell J. R. Gene therapy for duchenne muscular dystrophy: expectations and challenges. Arch Neurol: 2007; 64 9 1236 1241
33. Mendell J. R., Campbell K., Rodino-Klapac L., et al. Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med: 2010; 363 15 1429 1437
34. Mendell J. R., Rodino-Klapac L., Sahenk Z., et al. Gene therapy for muscular dystrophy: Lessons learned and path forward. Neurosci Lett: 2012;; Epub ahead of print
35. Tinsley J., Deconinck N., Fisher R., et al. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat Med: 1998; 4 12 1441 1444
36. Rooney J. E., Knapp J. R., Hodges B. L., Wuebbles R. D., Burkin D. J. Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-deficient congenital muscular dystrophy. Am J Pathol: 2012; 180 4 1593 1602
37. Martin P. T., Xu R., Rodino-Klapac L. R., et al. Overexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type mice. Am J Physiol Cell Physiol: 2009; 296 3 C476 C488
38. Bogdanovich S., Krag T. O., Barton E. R., et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature: 2002; 420 6914 418 421
39. Rodino-Klapac L. R., Haidet A. M., Kota J., Handy C., Kaspar B. K., Mendell J. R. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve: 2009; 39 3 283 296
40. Wagner K. R., McPherron A. C., Winik N., Lee S. J. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol: 2002; 52 6 832 836
41. Eagle M., Baudouin S. V., Chandler C., Giddings D. R., Bullock R., Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord: 2002; 12 10 926 929
42. Eagle M., Bourke J., Bullock R., et al. Managing Duchenne muscular dystrophythe additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord: 2007; 17 6 470 475
43. Viollet L., Thrush P. T., Flanigan K. M., Mendell J. R., Allen H. D. Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy. Am J Cardiol: 2012; 110 1 98 102
44. Duboc D., Meune C., Lerebours G., Devaux J. Y., Vaksmann G., Bécane H. M. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol: 2005; 45 6 855 857
45. Cohn R. D., van Erp C., Habashi J. P., et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med: 2007; 13 2 204 210
46. Hauser M. A., Horrigan S. K., Salmikangas P., et al. Myotilin is mutated in limb girdle muscular dystrophy 1A. Hum Mol Genet: 2000; 9 14 2141 2147
47. Olivé M., Goldfarb L. G., Shatunov A., Fischer D., Ferrer I. Myotilinopathy: refining the clinical and myopathological phenotype. Brain: 2005; 128 Pt 10 2315 2326
48. Selcen D., Engel A. G. Mutations in myotilin cause myofibrillar myopathy. Neurology: 2004; 62 8 1363 1371
49. Muchir A., Bonne G., van der Kooi A. J., et al. Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B). Hum Mol Genet: 2000; 9 9 1453 1459
50. van der Kooi A. J., Ledderhof T. M., de Voogt W. G., et al. A newly recognized autosomal dominant limb girdle muscular dystrophy with cardiac involvement. Ann Neurol: 1996; 39 5 636 642
51. Benedetti S., Menditto I., Degano M., et al. Phenotypic clustering of lamin A/C mutations in neuromuscular patients. Neurology: 2007; 69 12 1285 1292
52. Minetti C., Sotgia F., Bruno C., et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet: 1998; 18 4 365 368
53. Kubisch C., Schoser B. G., von Düring M., et al. Homozygous mutations in caveolin-3 cause a severe form of rippling muscle disease. Ann Neurol: 2003; 53 4 512 520
54. Fulizio L., Nascimbeni A. C., Fanin M., et al. Molecular and muscle pathology in a series of caveolinopathy patients. Hum Mutat: 2005; 25 1 82 89
55. Sarparanta J., Jonson P. H., Golzio C., et al. Mutations affecting the cytoplasmic functions of the co-chaperone DNAJB6 cause limb-girdle muscular dystrophy. Nat Genet: 2012; 44 4 450 455, S1-S2
56. Harms M. B., Sommerville R. B., Allred P., et al. Exome sequencing reveals DNAJB6 mutations in dominantly-inherited myopathy. Ann Neurol: 2012; 71 3 407 416
57. Bushby K. M., Beckmann J. S. The 105th ENMC sponsored workshop: pathogenesis in the non-sarcoglycan limb-girdle muscular dystrophies, Naarden, April 12-14, 2002. Neuromuscul Disord: 2003; 13 1 80 90
58. Richard I., Broux O., Allamand V., et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell: 1995; 81 1 27 40
59. Bashir R., Britton S., Strachan T., et al. A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet: 1998; 20 1 37 42
60. Anderson L. V., Harrison R. M., Pogue R., et al. Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies). Neuromuscul Disord: 2000; 10 8 553 559
61. Vainzof M., Anderson L. V., McNally E. M., et al. Dysferlin protein analysis in limb-girdle muscular dystrophies. J Mol Neurosci: 2001; 17 1 71 80
62. Walter M. C., Braun C., Vorgerd M., et al. Variable reduction of caveolin-3 in patients with LGMD2B/MM. J Neurol: 2003; 250 12 1431 1438
63. Noguchi S., McNally E. M., Ben Othmane K., et al. Mutations in the dystrophin-associated protein gamma-sarcoglycan in chromosome 13 muscular dystrophy. [see comments] Science: 1995; 270 5237 819 822
64. Roberds S. L., Leturcq F., Allamand V., et al. Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy. Cell: 1994; 78 4 625 633
65. Lim L. E., Duclos F., Broux O., et al. Beta-sarcoglycan: characterization and role in limb-girdle muscular dystrophy linked to 4q12. Nat Genet: 1995; 11 3 257 265
66. Nigro V., Piluso G., Belsito A., et al. Identification of a novel sarcoglycan gene at 5q33 encoding a sarcolemmal 35 kDa glycoprotein. Hum Mol Genet: 1996; 5 8 1179 1186
67. Bolduc V., Marlow G., Boycott K. M., et al. Recessive mutations in the putative calcium-activated chloride channel Anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies. Am J Hum Genet: 2010; 86 2 213 221
68. Schessl J., Kress W., Schoser B. Novel ANO5 mutations causing hyper-CK-emia, limb girdle muscular weakness and Miyoshi type of muscular dystrophy. Muscle Nerve: 2012; 45 5 740 742
69. Hicks D., Sarkozy A., Muelas N., et al. A founder mutation in anoctamin 5 is a major cause of limb-girdle muscular dystrophy. Brain: 2011; 134 Pt 1 171 182
70. Brockington M., Blake D. J., Prandini P., et al. Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. Am J Hum Genet: 2001; 69 6 1198 1209
71. Schwartz M., Hertz J. M., Sveen M. L., Vissing J. LGMD2I presenting with a characteristic Duchenne or Becker muscular dystrophy phenotype. Neurology: 2005; 64 9 1635 1637
72. Mendell J. R., Rodino-Klapac L. R., Rosales X. Q., et al. Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol: 2010; 68 5 629 638
73. Grose W. E., Clark K. R., Griffin D., et al. Homologous recombination mediates functional recovery of dysferlin deficiency following AAV5 gene transfer. PLoS ONE: 2012; 7 6 e39233
74. Flanigan K. M., Coffeen C. M., Sexton L., Stauffer D., Brunner S., Leppert M. F. Genetic characterization of a large, historically significant Utah kindred with facioscapulohumeral dystrophy. Neuromuscul Disord: 2001; 11 6-7 525 529
75. Awerbuch G. I., Nigro M. A., Wishnow R. Beevor's sign and facioscapulohumeral dystrophy. Arch Neurol: 1990; 47 11 1208 1209
76. Bushby K. M., Pollitt C., Johnson M. A., Rogers M. T., Chinnery P. F. Muscle pain as a prominent feature of facioscapulohumeral muscular dystrophy (FSHD): four illustrative case reports. Neuromuscul Disord: 1998; 8 8 574 579
77. Flanigan K. M. Facioscapulohumeral muscular dystrophy and scapuloperoneal syndromes. In: Engel A. D., Franzini-Armstrong C., eds. Myology. 3rd ed. New York McGraw-Hill: 2004
78. Lunt P. W., Jardine P. E., Koch M. C., et al. Correlation between fragment size at D4F104S1 and age at onset or at wheelchair use, with a possible generational effect, accounts for much phenotypic variation in 4q35-facioscapulohumeral muscular dystrophy (FSHD). [published erratum appears in Hum Mol Genet 1995 Jul;4(7):1243-4] Hum Mol Genet: 1995; 4 5 951 958
79. Tawil R., Forrester J., Griggs R. C., et al. The FSH-DY Group Evidence for anticipation and association of deletion size with severity in facioscapulohumeral muscular dystrophy. Ann Neurol: 1996; 39 6 744 748
80. Zatz M., Marie S. K., Passos-Bueno M. R., et al. High proportion of new mutations and possible anticipation in Brazilian facioscapulohumeral muscular dystrophy families. Am J Hum Genet: 1995; 56 1 99 105
81. Brouwer O. F., Padberg G. W., Ruys C. J., Brand R., de Laat J. A., Grote J. J. Hearing loss in facioscapulohumeral muscular dystrophy. Neurology: 1991; 41 12 1878 1881
82. Padberg G. W., Brouwer O. F., de Keizer R. J., et al. On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy. Muscle Nerve: 1995; 2 S73 S80
83. Rogers M. T., Zhao F., Harper P. S., Stephens D. Absence of hearing impairment in adult onset facioscapulohumeral muscular dystrophy. Neuromuscul Disord: 2002; 12 4 358 365
84. Fitzsimons R. B., Gurwin E. B., Bird A. C. Retinal vascular abnormalities in facioscapulohumeral muscular dystrophy. A general association with genetic and therapeutic implications. Brain: 1987; 110 Pt 3 631 648
85. Bodensteiner J. B., Schochet S. S. Facioscapulohumeral muscular dystrophy: the choice of a biopsy site. Muscle Nerve: 1986; 9 6 544 547
86. Arahata K., Ishihara T., Fukunaga H., et al. Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses. Muscle Nerve: 1995; 2 S56 S66
87. Figarella-Branger D., Pellissier J. F., Serratrice G., Pouget J., Bianco N. [Immunocytochemical study of the inflammatory forms of facioscapulohumeral myopathies and correlation with other types of myositis]. Ann Pathol: 1989; 9 2 100 108
88. Menga W. J. et al. Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. Nat Genet: 1992; 2 26 30
89. Lemmers R. JLF, van der Maarel S. M., van Deutekom J. CT., et al. Inter- and intrachromosomal sub-telomeric rearrangements on 4q35: implications for facioscapulohumeral muscular dystrophy (FSHD) aetiology and diagnosis. Hum Mol Genet: 1998; 7 1207 1214
90. van Overveld P. G., Lemmers R. J., Sandkuijl L. A., et al. Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy. Nat Genet: 2003; 35 4 315 317
91. de Greef J. C., Lemmers R. JLF, Camaño P., et al. Clinical features of facioscapulohumeral muscular dystrophy type 2. Neurology: 2010; 75 1548 1554
92. Lemmers R. J., van der Vliet P. J., Klooster R., et al. A unifying genetic model for facioscapulohumeral muscular dystrophy. Science: 2010; 329 5999 1650 1653
93. Wallace L. M., Liu J., Domire J. S., et al. RNA interference inhibits DUX4-induced muscle toxicity in vivo: implications for a targeted FSHD therapy. Mol Ther: 2012; 20 7 1417 1423
94. Wallace L. M., Garwick S. E., Mei W., et al. DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo. Ann Neurol: 2011; 69 3 540 552
95. Voet N. B., van der Kooi E. L., Riphagen I. I., Lindeman E., van Engelen B. G., Geurts ACh. Strength training and aerobic exercise training for muscle disease. Cochrane Database Syst Rev: 2010; 1 CD003907
96. Bertini E., D'Amico A., Gualandi F., Petrini S. Congenital muscular dystrophies: a brief review. Semin Pediatr Neurol: 2011; 18 4 277 288
97. Sparks S. E., Escolar D. M. Congenital muscular dystrophies. Handb Clin Neurol: 2011; 101 47 79
98. Helbling-Leclerc A., Zhang X., Topaloglu H., et al. Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. Nat Genet: 1995; 11 2 216 218
99. Martin P. T. Congenital muscular dystrophies involving the O-mannose pathway. Curr Mol Med: 2007; 7 4 417 425
100. Mercuri E., Messina S., Bruno C., et al. Congenital muscular dystrophies with defective glycosylation of dystroglycan: a population study. Neurology: 2009; 72 21 1802 1809
101. Godfrey C., Clement E., Mein R., et al. Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. Brain: 2007; 130 Pt 10 2725 2735
102. Fukuyama Y., Osawa M., Suzuki H. Congenital progressive muscular dystrophy of the Fukuyama type - clinical, genetic and pathological considerations. Brain Dev: 1981; 3 1 1 29
103. Balci B., Uyanik G., Dincer P., et al. An autosomal recessive limb girdle muscular dystrophy (LGMD2) with mild mental retardation is allelic to Walker-Warburg syndrome (WWS) caused by a mutation in the POMT1 gene. Neuromuscul Disord: 2005; 15 4 271 275
104. Vuillaumier-Barrot S., Quijano-Roy S., Bouchet-Seraphin C., et al. Four Caucasian patients with mutations in the fukutin gene and variable clinical phenotype. Neuromuscul Disord: 2009; 19 3 182 188
105. Biancheri R., Falace A., Tessa A., et al. POMT2 gene mutation in limb-girdle muscular dystrophy with inflammatory changes. Biochem Biophys Res Commun: 2007; 363 4 1033 1037
106. Clement E. M., Godfrey C., Tan J., et al. Mild POMGnT1 mutations underlie a novel limb-girdle muscular dystrophy variant. Arch Neurol: 2008; 65 1 137 141
107. Higuchi I., Shiraishi T., Hashiguchi T., et al. Frameshift mutation in the collagen VI gene causes Ullrich's disease. Ann Neurol: 2001; 50 2 261 265
108. Camacho Vanegas O., Bertini E., Zhang R. Z., et al. Ullrich scleroatonic muscular dystrophy is caused by recessive mutations in collagen type VI. Proc Natl Acad Sci U S A: 2001; 98 13 7516 7521
109. Nadeau A., Kinali M., Main M., et al. Natural history of Ullrich congenital muscular dystrophy. Neurology: 2009; 73 1 25 31
110. Lampe A. K., Dunn D. M., von Niederhausern A. C., et al. Automated genomic sequence analysis of the three collagen VI genes: applications to Ullrich congenital muscular dystrophy and Bethlem myopathy. J Med Genet: 2005; 42 2 108 120
111. Okada M., Kawahara G., Noguchi S., et al. Primary collagen VI deficiency is the second most common congenital muscular dystrophy in Japan. Neurology: 2007; 69 10 1035 1042
112. Peat R. A., Smith J. M., Compton A. G., et al. Diagnosis and etiology of congenital muscular dystrophy. Neurology: 2008; 71 5 312 321
113. Pace R. A., Peat R. A., Baker N. L., et al. Collagen VI glycine mutations: perturbed assembly and a spectrum of clinical severity. Ann Neurol: 2008; 64 3 294 303
114. Jöbsis G. J., Keizers H., Vreijling J. P., et al. Type VI collagen mutations in Bethlem myopathy, an autosomal dominant myopathy with contractures. Nat Genet: 1996; 14 1 113 115
115. Foley A. R., Hu Y., Zou Y., et al. Autosomal recessive inheritance of classic Bethlem myopathy. Neuromuscul Disord: 2009; 19 12 813 817
116. Allamand V., Briñas L., Richard P., Stojkovic T., Quijano-Roy S., Bonne G. ColVI myopathies: where do we stand, where do we go? Skelet Muscle: 2011; 1 30
117. Lampe A. K., Bushby K. M. Collagen VI related muscle disorders. J Med Genet: 2005; 42 9 673 685
118. Moghadaszadeh B., Petit N., Jaillard C., et al. Mutations in SEPN1 cause congenital muscular dystrophy with spinal rigidity and restrictive respiratory syndrome. Nat Genet: 2001; 29 1 17 18
119. Flanigan K. M., Kerr L., Bromberg M. B., et al. Congenital muscular dystrophy with rigid spine syndrome: a clinical, pathological, radiological, and genetic study. Ann Neurol: 2000; 47 2 152 161
120. Scoto M., Cirak S., Mein R., et al. SEPN1-related myopathies: clinical course in a large cohort of patients. Neurology: 2011; 76 24 2073 2078
121. Clarke N. F., Kidson W., Quijano-Roy S., et al. SEPN1: associated with congenital fiber-type disproportion and insulin resistance. Ann Neurol: 2006; 59 3 546 552
122. Ferreiro A., Ceuterick-de Groote C., Marks J. J., et al. Desmin-related myopathy with Mallory body-like inclusions is caused by mutations of the selenoprotein N gene. Ann Neurol: 2004; 55 5 676 686
123. Ferreiro A., Quijano-Roy S., Pichereau C., et al. Mutations of the selenoprotein N gene, which is implicated in rigid spine muscular dystrophy, cause the classical phenotype of multiminicore disease: reassessing the nosology of early-onset myopathies. Am J Hum Genet: 2002; 71 4 739 749
124. Castets P., Lescure A., Guicheney P., Allamand V. Selenoprotein N in skeletal muscle: from diseases to function. J Mol Med (Berl): 2012
125. Barresi R., Michele D. E., Kanagawa M., et al. LARGE can functionally bypass alpha-dystroglycan glycosylation defects in distinct congenital muscular dystrophies. Nat Med: 2004; 10 7 696 703
126. Xu R., DeVries S., Camboni M., Martin P. T. Overexpression of Galgt2 reduces dystrophic pathology in the skeletal muscles of alpha sarcoglycan-deficient mice. Am J Pathol: 2009; 175 1 235 247
127. Xu R., Chandrasekharan K., Yoon J. H., Camboni M., Martin P. T. Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A. Am J Pathol: 2007; 171 1 181 199
128. Merlini L., Sabatelli P., Armaroli A., et al. Cyclosporine A in Ullrich congenital muscular dystrophy: long-term results. Oxid Med Cell Longev: 2011; 2011 139194 139194